Value and limitation of immunohistochemical expression of HMGA2 in mesenchymal tumors: About a series of 1052 cases

Modern Pathology

Volumn 23, Issue 12, 2010, Pages 1657-1666

  Dreux, Nadège ^a   Marty, Marion ^a   Chibon, Frédéric ^a   Vélasco, Valérie ^a   Hostein, Isabelle ^a   Ranchère Vince, Dominique ^b   Terrier, Philippe ^c   Coindre, Jean Michel ^a,d  

^a INSTITUT BERGONIÉ   (France)

^b CENTRE LÉON BÉRARD   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

HMGA2; immunohistochemistry; mesenchymal tumor; tissue microarray

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN;

ADIPOSE TISSUE; ARTICLE; CONTROLLED STUDY; DERMATOFIBROMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MESENCHYMOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DIFFERENTIATION; TISSUE MICROARRAY;

EID: 78649689358     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.174     Document Type: Article

References (50)

1. Giancotti V, Bandiera A, Buratti E, et al. Comparison of multiple forms of the high mobility group I proteins in rodent and human cells. Identification of the human high mobility group I-C protein. Eur J Biochem 1991;198:211-216.
2. Johnson KR, Cook SA, Davisson MT. Chromosomal localization of the murine gene and two related sequences encoding high-mobility-group I and Y proteins. Genomics 1992;12:503-509.
3. Fedele M, Battista S, Manfioletti G, et al. Role of the high mobility group A proteins in human lipomas. Carcinogenesis 2001;22:1583-1591.
4. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007;7:899-910.
5. Narita M, Krizhanovsky V, Nunez S, et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006;126: 503-514.
6. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001;277:63-81.
7. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-1030.
8. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007;315:1576-1579.
9. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439-2446.
10. Hirning-Folz U, Wilda M, Rippe V, et al. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 1998;23:350-357.
11. Li O, Li J, Droge P. DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells. FEBS Lett 2007;581:3533-3537.
12. Rogalla P, Drechsler K, Frey G, et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 1996;149:775-779.
13. Abe N, Watanabe T, Masaki T, et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res 2000;60:3117-3122.
14. Fabjani G, Tong D, Wolf A, et al. HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep 2005;14:737-741.
15. Hristov AC, Cope L, Reyes MD, et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocar-cinoma. Mod Pathol 2009;22:43-49.
16. Meyer B, Loeschke S, Schultze A, et al. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 2007;46:503-511.
17. Motoyama K, Inoue H, Nakamura Y, et al. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 2008;14:2334-2340.
18. Miyazawa J, Mitoro A, Kawashiri S, et al. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 2004;64: 2024-2029.
19. Hess JL. Chromosomal translocations in benign tumors: the HMGI proteins. Am J Clin Pathol 1998;109: 251-261.
20. Schoenmakers EF, Geurts JM, Kools PF, et al. A 6-Mb yeast artificial chromosome contig and long-range physical map encompassing the region on chromosome 12q15 frequently rearranged in a variety of benign solid tumors. Genomics 1995;29:665-678.
21. Dahlen A, Mertens F, Rydholm A, et al. Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas. Mod Pathol 2003;16: 1132-1140.
22. Ingraham SE, Lynch RA, Surti U, et al. Identification and characterization of novel human transcripts embedded within HMGA2 in t(12;14)(q15;q24.1) uterine leiomyoma. Mutat Res 2006;602:43-53.
23. Mine N, Kurose K, Nagai H, et al. Gene fusion involving HMGIC is a frequent aberration in uterine leiomyomas. J Hum Genet 2001;46:408-412. (Pubitemid 32634515)
24. Ashar HR, Tkachenko A, Shah P, et al. HMGA2 is expressed in an allele-specific manner in human lipomas. Cancer Genet Cytogenet 2003;143:160-168.
25. Nilsson M, Mertens F, Hoglund M, et al. Truncation and fusion of HMGA2 in lipomas with rearrangements of 5q32-4q33 and 12q14-4q15. Cytogenet Genome Res 2006;112:60-66.
26. Petit MM, Schoenmakers EF, Huysmans C, et al. LHFP, a novel translocation partner gene of HMGIC in a lipoma, is a member of a new family of LHFP-like genes. Genomics 1999;57:438-441.
27. Bartuma H, Panagopoulos I, Collin A, et al. Expression levels of HMGA2 in adipocytic tumors correlate with morphologic and cytogenetic subgroups. Mol Cancer 2009;8:36.
28. Dei Tos AP, Doglioni C, Piccinin S, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000;190:531-536.
29. Tallini G, Dal Cin P, Rhoden KJ, et al. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol 1997;151:37-43.
30. Arlotta P, Tai AK, Manfioletti G, et al. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J Biol Chem 2000;275: 14394-14400.
31. Bartuma H, Hallor KH, Panagopoulos I, et al. Assessment of the clinical and molecular impact of different cytogenetic subgroups in a series of 272 lipomas with abnormal karyotype. Genes Chromosomes Cancer 2007;46:594-606.
32. Italiano A, Bianchini L, Keslair F, et al. HMGA2 is the partner of MDM2 in well-differentiated and dediffer-entiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008;122: 2233-2241.
33. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007;31: 1476-1489.
34. Li N, McNiff J, Hui P, et al. Differential expression of HMGA1 and HMGA2 in dermatofibroma and derma-tofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity. Am J Dermatopathol 2004;26:267-272.
35. Zhou X, Benson KF, Ashar HR, et al. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-774.
36. Battista S, Fidanza V, Fedele M, et al. The expression of truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 1999;59: 4793-4797.
37. Schoenmakers EF, Wanschura S, Mols R, et al. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumors. Nat Genet 1995;10:436-444.
38. Tallini G, Dal Cin P. HMGI(Y) and HMGI-C dysregula-tion: a common occurrence in human tumors. Adv Anat Pathol 1999;6:237-246.
39. Ayoubi TA, Jansen E, Meulemans SM, et al. Regulation of HMGIC expression : an architectural transcription factor involved in growth control and development. Oncogene 1999;18:5076-5087.
40. Kazmierczak B, Pohnke Y, Bullerdiek J. Fusion transcripts between the HMGIC gene and RTVL-H-related sequences in mesenchymal tumors without cytogenetic aberrations. Genomics 1996;38:223-226.
41. Nilbert M, Heim S, Mandahl N, et al. Characteristic chromosome abnormalities, including rearrangements of 6p, del(7q), +12, and t(12;14), in 44 uterine leiomyomas. Hum Genet 1990;85:605-611.
42. Rein MS, Friedman AJ, Barbieri RL, et al. Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol 1991;77:923-926.
43. Gross KL, Neskey DM, Manchanda N, et al. HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. Genes Chromosomes Cancer 2003;38:68-79.
44. Peng Y, Laser J, Shi G, et al. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 2008;6:663-673.
45. Horsman D, Berean K. Aggressive angiomyxoma of the pelvis: cytogenetic findings in a single case. Cancer Genet and Cytogenet. [Abstract] 1991;56:130.
46. Betz J, Meloni A, Moore G. Cytogenetics findings in a case of angiomyxoma of the vaginal wall. Cancer Genet Cytogenet 1995 Abstract 84:157.
47. Kazmierczak B, Dal Cin P, Wanschura S. Involvement of the MAR genes in two rares benign mesenchymal tumors: a hamartoma of the breast and a aggressive angiomyxoma. Cancer Genet Cytogenet. [Abstract] 1995;84:148.
48. Nucci MR, Weremowicz S, Neskey DM, et al. Chromosomal translocation t(8;12) Induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva. Genes Chromosomes Cancer 2001;32:172-176.
49. Medeiros F, Erickson-Johnson MR, Keeney GL, et al. Frequency and characterization of HMGA2 and HMGA1 rearrangements in mesenchymal tumors of the lower genital tract. Genes Chromosomes Cancer 2007;46:981-990.
50. Medeiros F, Oliveira A, Llyod R. HMGA2 expression was a biomarker for aggressive angiomyxoma. Mod Pathol. [Abstract]. 2008;21:214A.